Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Gains from Sales and Divestitures (2022)

Alx Oncology Holdings' Gains from Sales and Divestitures history spans 1 years, with the latest figure at $53774.0 for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $53774.0; the TTM value through Dec 2022 reached $53774.0, changed N/A, while the annual FY2022 figure was $53774.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $53774.0 at Alx Oncology Holdings, up from $3701.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $53774.0 in Q4 2022 and bottomed at $1888.0 in Q1 2022.